Neurocrine Biosciences, Inc.
US ˙ NasdaqGS ˙ US64125C1099

SecurityNBIX / Neurocrine Biosciences, Inc.
InstitutionAviva Plc
Latest Disclosed Ownership71,310 shares
Latest Disclosed Value $ 9,394,379
Aviva Plc reports 1.26% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 14, 2026 - Aviva Plc filed a 13F-HR form disclosing ownership of 71,310 shares of Neurocrine Biosciences, Inc. (US:NBIX) valued at $9,394,379 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 70,423 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 1.26% during the quarter. The current value of the position is $11,773,994 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 71,310 887 1.26 9,394 -5.95 0.0158
2026-02-12 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 70,423 3,784 5.68 9,988 6.78 0.0168
2025-11-13 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 66,639 4,893 7.92 9,355 20.54 0.0170
2025-08-07 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 61,746 56,420 1,059.33 7,761 1,217.49 0.0160
2025-05-15 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,326 -56,592 -91.40 589 -93.03 0.0014
2025-02-13 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 61,918 37,826 157.01 8,452 204.54 0.0220
2024-11-14 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 24,092 -39,459 -62.09 2,776 -68.28 0.0072
2024-08-02 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 63,551 -1,411 -2.17 8,749 -2.34 0.0243
2024-05-14 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 64,962 5,994 10.16 8,960 15.32 0.0295
2024-02-09 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 58,968 44,182 298.81 7,770 367.17 0.0279
2023-11-13 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,786 14,786 1,663 0.0070
2023-02-14 2022-12-31 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 0 -18,036 -100.00 0 -100.00
2023-02-10 2022-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 0 -18,036 0
2023-02-09 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -18,036 0
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 18,036 -37,919 -67.77 1,916 -64.87 0.0110
2022-08-04 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 55,955 55,955 5,454 0.0290
2022-05-13 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -21,787 -100.00 0 -100.00
2022-02-10 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 21,787 21,787 1,856 0.0078
2021-08-10 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -13,950 -100.00 0 -100.00
2021-05-13 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,950 750 5.68 1,357 7.27 0.0066
2021-02-10 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,200 -9,622 -42.16 1,265 -42.37 0.0066
2020-11-12 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 22,822 4,623 25.40 2,195 -1.13 0.0129
2020-08-13 2020-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 18,199 -22,144 -54.89 2,220 -36.43 0.0138
2020-08-13 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 18,199 -22,144 2,220 6,720.8922
2020-05-14 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 40,343 23,615 141.17 3,492 94.22 0.0256
2020-02-10 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,728 16,728 1,798 0.0109
2014-11-13 2014-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -124,427 -100.00 0 -100.00
2014-08-13 2014-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 124,427 -85,197 -40.64 1,846 -5.72 0.0141
2014-02-13 2013-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 209,624 3,226 1.56 1,958 -16.18 0.0164
2013-11-13 2013-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 206,398 1,879 0.92 2,336 -14.62 0.0205
2013-08-01 2013-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 204,519 204,519 2,736 0.0277
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.